Practical oncology http://oncology.zaslavsky.com.ua/ <div align="center"><table id="table1" style="border-collapse: collapse;" width="100%" border="0"><tbody><tr><td colspan="2" align="center" valign="top"> <b> <span lang="EN-GB" style="font-size: 10pt; line-height: 107%; font-family: Verdana"> Occupational research specialized peer-reviewed publication for oncologists, surgeons and other specialty doctors reported on current issues on diagnosis and treatment of oncology disorders from a scientific and practical standpoint.</span></b></td></tr><tr><td colspan="2" align="center" valign="top"><hr noshade="noshade" size="1" /></td></tr><tr> <td align="left" valign="top" width="19%"> <img style="border: 0px; cursor: default; color: #000000; font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 10px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: -webkit-left; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;" src="/public/journals/614/journalThumbnail_uk_UA.jpg" alt="" width="250" height="375" hspace="10" /></td> <td align="left" valign="top" width="80%"><span style="font-size: 10pt; font-family: Verdana;"> <strong>The founder:<span class="Apple-converted-space"> </span></strong></span><span style="font-size: 10pt; font-family: Verdana;">Zaslavsky O.Yu.</span><span style="font-size: 10pt; font-family: Verdana;"><br /> <strong>Publisher:</strong><span class="Apple-converted-space"> </span>Zaslavsky O.Yu.<br /> <strong>Language of edition:</strong><span class="Apple-converted-space"> </span>Ukrainian, English, Russian.</span><p><span style="font-size: 10pt; font-family: Verdana;"> <strong>Registration Certificate:<span class="Apple-converted-space"> </span></strong></span><strong><span lang="EN-GB" style="font-size: 10pt; line-height: 107%; font-family: Verdana">Registration Certificate:</span></strong><span class="apple-converted-space"><span lang="EN-GB" style="font-size: 10pt; line-height: 107%; font-family: Verdana">&nbsp;</span></span><span style="font-size: 10pt; line-height: 107%; font-family: Verdana">КВ</span><span lang="EN-GB" style="font-size: 10pt; line-height: 107%; font-family: Verdana"> № 23434-13274</span><span style="font-size: 10pt; line-height: 107%; font-family: Verdana">Р</span><span lang="EN-GB" style="font-size: 10pt; line-height: 107%; font-family: Verdana">. Issued by the Ministry of Justice of Ukraine 22.06.2018.</span></p><p><strong style="font-family: Verdana; font-size: 10pt;"> Publication frequency:<span class="Apple-converted-space"> </span></strong><span style="font-family: Verdana; font-size: 10pt;">4 times per year.<br /> <strong>Founded: </strong>November 2018</span></p><p><strong style="font-family: Verdana; font-size: 10pt;">ISSN<span style="font-size: 10pt; font-family: Verdana;"> 2663-3272 (print)<br /> <span style="font-family: Verdana; font-size: 10pt;">ISSN</span> 2663-3280 (online)</span></strong></p><strong style="color: #000000; font-family: Verdana; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; line-height: normal; orphans: 2; text-align: -webkit-left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;"> <span lang="EN-GB"> <a style="color: blue; text-underline: single; text-decoration: none;" href="http://www.mif-ua.com/"> http://www.mif-ua.com/</a></span></strong></td></tr></tbody></table></div> <table id="table2" width="100%" border="0"><tr><td valign="top" width="98%"><hr></td></tr><tr> <td valign="top" width="98%" align="center"> <a target="_blank" style="text-decoration: none; color: rgb(10, 31, 84); font-family: Verdana; font-size: 12px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background: rgb(251, 251, 243)" href="https://search.crossref.org/?q=2663-3280"> <img src="http://www.mif-ua.com/media/uploads/index/cr.jpg" alt="" width="100" height="37"></a>&nbsp;<a target="_blank" style="text-decoration: none; color: rgb(47, 75, 146); font-family: Verdana; font-size: 12px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(251, 251, 243);" href="https://www.worldcat.org/search?q=n2:2663-3272&qt=advanced&dblist=638"><img src="http://www.mif-ua.com/media/uploads/index/w-c.jpg" alt="" width="100" height="37"></a>&nbsp;<a target="_blank" style="text-decoration: none; color: rgb(47, 75, 146); font-family: Verdana; font-size: 12px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(251, 251, 243);" href="https://scholar.google.com.ua/scholar?hl=en&as_sdt=0,5&q=2663-3280&btnG="><img src="http://www.mif-ua.com/media/uploads/index/google.jpg" alt="" width="100" height="37"></a>&nbsp;<a href="https://www.base-search.net/Search/Results?type=all&lookfor=Практична+онкологія+2663-3272&ling=1&oaboost=1&name=&thes=&refid=dcresen&newsearch=1" target="_blank"><img src="http://www.mif-ua.com/media/uploads/index/base.jpg" alt="" width="100" height="37"></a> <a href="https://sfdora.org/" target="_blank"> <img src="http://www.mif-ua.com/media/uploads/index/dora.jpg" alt="" width="100" height="37"></a></td></tr></table> Natural Person-entreprenuer Zaslavsky O.Yu. en-US Practical oncology 2663-3272 <p>Our edition uses the copyright terms of <strong>Creative Commons</strong> for open access journals.</p><p>Authors, who are published in this journal, agree with the following terms:</p><ol><li>The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a <a href="http://creativecommons.org/licenses/by/4.0/"><strong>Creative Commons Attribution 4.0 International License</strong></a>, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.</li><li>Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.</li><li>The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.</li><li>The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.</li><li>The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.</li><li>The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.</li><li>The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal. </li></ol> Perioperative chemotherapy for locally advanced operable gastric cancer (literature review) http://oncology.zaslavsky.com.ua/article/view/229866 <p><strong>Background.</strong> Gastric cancer remains the leading cause of cancer morbidity and mortality in the world. According to Globocan, in 2020 the incidence of gastric cancer was 5.6 % (1,089,103 people), with mortality of 7.7 % (768,793 people). According to the Cancer Registry of Ukraine for 2017–2018, gastric cancer is the second leading cause of death after lung cancer in men. By the time of diagnosis, almost 70 % of patients have a locally advanced or generalized tumor process, which reduces the possibi­lity of radical surgical treatment. Surgical treatment remains the main method of treatment for gastric cancer, but the prognosis is poor even after high-quality surgical treatment due to the high frequency of recurrences (20–60 %) and insufficient effectiveness of adjuvant therapy. The purpose of the study: to analyze studies that have tested various schemes of neoadjuvant treatment for gastric cancer and to present the results of key promising studies on this treatment technology. <strong>Materials and methods.</strong> We conducted a literature review that included randomized and nonrandomized clinical trials from 2010 to 2020. The search was conducted using electronic scientometric databases PubMed, Embase, Scopus, Web of Science, MedLine, Cochrane Library, as well as abstracts of the annual congresses of the American Society of Clinical Oncology and the European Society for Medical Oncology. The key words of the search were: neoadjuvant chemotherapy, perioperative chemotherapy, gastric neoplasm, gastric cancer, randomized controlled trial, treatment of gastric cancer, disseminated gastric cancer, D2 dissection. The selection criteria were: studies comparing different regimens of perioperative chemotherapy without the addition of chemoradiation therapy, targeted therapy over the past 10 years. <strong>Results.</strong> Thirty publications were found for the above-mentioned keywords. Among these sources, there were 10 randomized clinical trials, 8 non-randomized clinical trials, 4 meta-analyzes, 8 li­terature reviews. <strong>Conclusions.</strong> Analysis of these data indicates the presence of only 3 randomized controlled trials on the efficacy and safety of perioperative chemotherapy for locally advanced gastric cancer that met the selection criteria. There are shortcomings in the design of the analyzed studies: no reliable data on adequate lymph dissection, inclusion into the study of patients not only with gastric cancer, but also with other cancer sites (gastroesophageal adenocarcinoma, cancer of the lower esophagus). The above arguments suggest that the recognition of the FLOT as the only effective and safe regimen for neoadjuvant polychemotherapy in locally advanced gastric cancer is not a well-founded postulate, but requires further planned clinical trials of appropriate quality.</p> K.D. Bakhniuk Copyright (c) 2021 http://creativecommons.org/licenses/by/4.0 2021-05-17 2021-05-17 4 1 5 10 10.22141/2663-3272.4.1.2021.229866 Optimal integration of CDK4/6 inhibitors for treatment of hormone receptor-positive metastatic breast cancer http://oncology.zaslavsky.com.ua/article/view/229867 <p>The paper analyzes the effectiveness of a new class of medications — CDK4/6 cyclin-dependent kinases inhibitors and discover the mechanism of its action. The article describes the general results of studies on palbociclib, ribociclib and abemaciclib* for the first- and subsequent-line of the therapy of HR-positive/HER2-negative metastatic breast cancer. The profile of adverse events of approved CDK4/6 inhibitors are considered. The combination of CDK4/6 inhibitors with endocrine therapy was shown to have benefits in survival, potentiality to reduce hormone resistance and great perspectives to improve clinical results of hormone receptor-positive metastatic breast cancer.</p> D.Ye. Ryspayeva Copyright (c) 2021 http://creativecommons.org/licenses/by/4.0 2021-05-17 2021-05-17 4 1 11 18 10.22141/2663-3272.4.1.2021.229867 The effect of vitamin D on the development and course of breast cancer (literature review) http://oncology.zaslavsky.com.ua/article/view/229868 <p>Breast cancer is the most common cancer among the female population worldwide. The incidence of breast cancer is increasing every year. This requires the search for new trigger factors that can contribute to the onset and course of this disease. One of these factors is vitamin D, which is constantly deficient in most of the world’s population. This article provides a review of clinical studies over the last 15 years on the relationship between serum vitamin D concentration and breast cancer risk, prognostic factors, survival and treatment outcomes, and the effect of vitamin D receptor status on breast cancer. Studies have shown heterogeneity in research results that found the relationship between low vitamin D levels and breast cancer risk, prognostic factors and survival. There was no heterogeneity in studies showing an association between decreased vitamin D receptor status and worse prognosis. The situation was similar when studying the effect of vitamin D on impro­ving treatment outcomes. Despite conflicting research results, most studies show a correlation between vitamin D deficiency and breast cancer risk, prognostic factors, survival and treatment outcomes. Therefore, the selected vector of scientific researches is rational both from the point of view of eliminating the pandemic of vitamin D deficiency among the world’s population and preventing the spread of breast cancer.</p> M.V. Pavlushenko R.V. Lyubota O.S. Zotov M.F. Anikusko R.I. Vereshchako Copyright (c) 2021 http://creativecommons.org/licenses/by/4.0 2021-05-17 2021-05-17 4 1 19 29 10.22141/2663-3272.4.1.2021.229868 Anticancer chemotherapy with high-dose methotrexate http://oncology.zaslavsky.com.ua/article/view/229869 <p>The literature review is devoted to the use of high doses of methotrexate in oncology. There is a brief historical overview of the use of methotrexate for the treatment of malignant neoplasms; the main mechanism of its cytotoxic effect on tumor cells, the development of resistance to methotrexate, the main indications for the use of high doses of methotrexate and the main side effects of this treatment are considered. The review details the results of using high doses of methotrexate in the treatment of patients with osteosarcoma, non-Hodgkin’s lymphomas, located mainly in the central nervous system, and acute lymphoblastic leukemia.</p> L.V. Hryvkova Copyright (c) 2021 http://creativecommons.org/licenses/by/4.0 2021-05-17 2021-05-17 4 1 30 38 10.22141/2663-3272.4.1.2021.229869 Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer (literature review) http://oncology.zaslavsky.com.ua/article/view/229870 <p><strong>Background.</strong> Breast cancer is the leading cancer type in women. Improvement in its management requires a continuous investigation of new tools for diagnosis and treatment. Biomarkers for breast cancer remain a field of great interest, despite existing knowledge. Extensive research recognizes the critical role played by tumor-infiltrating lymphocytes (TILs) in terms of prognosis and prediction, but much uncertainty still exists about the application of this biomarker in clinical practice. Thus, the purpose of this paper is to review recent researches about the role of TILs as a prognostic and predictive factor in the clinical management of breast cancer subtypes. <strong>Materials and methods.</strong> Eligible studies from Medline, Pubmed, Google Scholar (2010–2020) databases were analyzed and retrieved.<strong> Results.</strong> For primary tumors, a positive correlation was found between TILs and survival prognosis for HER2+ and TNBC subtypes, while for luminal subtypes it was a negative correlation. The predictive value of TILs in the neoadjuvant setting is established for HER2+, TNBC subtypes. In the case of using TILs as a predictive factor for HER2-targeted therapy, it remains a concern due to controversial data. For residual tumor, it is growing body of evidence about the positive correlation of TILs and prognosis for all subtypes, but data are limited. <strong>Conclusions.</strong> TILs were found to have prognostic and predictive value. However, due to the heterogeneity of breast cancer subtypes, TILs as a biomarker should be interpreted with caution. Further studies need to be carried out to determine the validity of making a clinical decision based on TILs count.</p> M.O. Bilych Copyright (c) 2021 http://creativecommons.org/licenses/by/4.0 2021-05-17 2021-05-17 4 1 39 44 10.22141/2663-3272.4.1.2021.229870 Appeal of Editor-in-Chief http://oncology.zaslavsky.com.ua/article/view/229871 <p>No abstract</p> Alexey Zotov Copyright (c) 2021 http://creativecommons.org/licenses/by/4.0 2021-05-17 2021-05-17 4 1 4 4 10.22141/2663-3272.4.1.2021.229871 Labeling as a method of routine monitoring of tumor response to therapy http://oncology.zaslavsky.com.ua/article/view/229872 <p>Surgical treatment is still one of the main methods of complex therapy of breast cancer. Due to the widespread use of non-adjuvant antitumor treatment, the issue of routine tumor labeling is becoming increasingly important. The purpose of labeling is to improve the quality of tumor control after neoadjuvant therapy and adequate surgical treatment. In this literature review, we will consider the methods for labeling to visualize a tumor site.</p> T.A. Kravchun A.A. Samusieva V.V. Zaichuk Copyright (c) 2021 http://creativecommons.org/licenses/by/4.0 2021-05-17 2021-05-17 4 1 45 51 10.22141/2663-3272.4.1.2021.229872